Stimunity logo

Stimunity

Stimunity is a preclinical-stage startup company which develops best-in-class drugs on the STING pathway to activate the innate immune system. Stimunity drugs stimulate patients immune system to fight back infectious pathogens or cancer.

Stimuntiy is hosted by Institut Curie and incubated by Paris Biotech Sant_ and technology is based on academic research work from: Institut Curie, the French National Institute of Health and Medical Research (Inserm) and University of Oxford.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://stimunity.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
24, rue du Faubourg Saint Jacques 75014
Paris
France
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/stimunity” connections=”true” suffix=””]

Stimunity focuses on the STING pathway, which is known to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells. By addressing this target with a unique biologic approach which combines the the endogenous STING activator encapsulated in a Virus-Like Particle (VLP), Stimunitys drugs are best-in-class.

In Feb 2018, Stimunity received 2M ‹ seed funding from Portage, a US/Canadian listed company actively investing in promising
companies that have the potential to be a game changer in the immunotherapy field. Earlier in June 2016, Stimunity received a non-dilutive financing of 60k ‹ from Scientip_le Initiative to complete the proof-of-concept package.